share_log

6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A

SEC announcement ·  Jul 23 11:29
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more